Loading...
Loading...
ROIV| Name | Value |
|---|---|
| Revenues | 4.5M |
| Cost of Revenue | 2.1M |
| Gross Profit | 2.4M |
| Operating Expense | 344.1M |
| Operating I/L | -341.7M |
| Other Income/Expense | 117.3M |
| Interest Income | 69.8M |
| Pretax | -224.4M |
| Income Tax Expense | 12.5M |
| Net Income/Loss | -230.2M |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company specializing in the research and development of medicines for various therapeutic areas. The company's product candidates target solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. Through the development of these product candidates, Roivant Sciences generates revenue by bringing innovative treatments to market and addressing unmet medical needs across a wide range of conditions.
